98%
921
2 minutes
20
To date, there is no available targeted therapy for patients who are diagnosed with triple-negative breast cancers (TNBC). The aim of this study was to identify a new specific target for specific treatments. Frozen primary tumors were collected from 83 adjuvant therapy-naive TNBC patients. These samples were used for global proteome profiling by iTRAQ-OFFGEL-LC-MS/MS approach in two series: a training cohort (n = 42) and a test set (n = 41). Patients who remains free of local or distant metastasis for a minimum of 5 years after surgery were classified in the no-relapse group; the others were in the relapse group. OPLS and Kaplan-Meier analyses were performed to select candidate markers, which were validated by immunohistochemistry. Three proteins were identified in the training set and validated in the test set by Kaplan-Meier method and immunohistochemistry (IHC): TrpRS as a good prognostic markers and DP and TSP1 as bad prognostic markers. We propose the establishment of an IHC test to calculate the score of TrpRS, DP, and TSP1 in TNBC tumors to evaluate the degree of aggressiveness of the tumors. Finally, we propose that DP and TSP1 could provide therapeutic targets for specific treatments.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4638037 | PMC |
http://dx.doi.org/10.1074/mcp.M115.048967 | DOI Listing |
J Pathol
September 2025
Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University, Baltimore, MD, USA.
Triple-negative breast cancer (TNBC) lacks expression of estrogen receptor (ER), progesterone receptor (PR), and HER2, and remains one of the most aggressive and therapeutically challenging breast cancer subtypes, marked by early relapse, metastasis, and limited targeted treatment options. In a recent study published in The Journal of Pathology, Kuo et al provide compelling evidence that nicotine exposure, whether from tobacco smoke or e-cigarette vapor, drives TNBC progression by promoting stem-like and metastatic phenotypes. Integrating clinical datasets, patient tissues, cell lines, and in vivo models, the authors demonstrate that nicotine enhances tumor aggressiveness via coordinated upregulation of CHRNA9 and IGF1R.
View Article and Find Full Text PDFFEBS Lett
September 2025
Department of Translational Medicine, University of Ferrara, Italy.
This study, based on datasets from healthy tissues, lactating mammary epithelial cells, and breast cancer phenotypes, investigates mammary gland pathophysiology at single-cell resolution to identify key regulators in breast cancer development and to gain a deeper understanding of its biology and heterogeneity. We suggest that antileukoproteinase (SLPI) has prognostic value associated with metastasis in basal breast cancers. Our analysis highlights the similarity between triple-negative breast cancer cells and mature luminal lactocytes, which share active regulons (SOX2, MTHFD1, POU4F3, and ZNF32), suggesting conserved molecular mechanisms.
View Article and Find Full Text PDFJ Environ Pathol Toxicol Oncol
September 2025
Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China.
Noncoding RNA regulatory networks play crucial roles in human breast cancer. The aim of this study was to establish a network containing multi-type RNAs and RBPs in triple-negative breast cancer (TNBC). Differential expression analyses of lncRNAs, miRNAs, and genes were performed using the GEO2R tool.
View Article and Find Full Text PDFJ Ultrasound Med
September 2025
Department of Ultrasound, Donghai Hospital Affiliated to Kangda College of Nanjing Medical University, Lianyungang, China.
Objective: The aim of this study is to evaluate the prognostic performance of a nomogram integrating clinical parameters with deep learning radiomics (DLRN) features derived from ultrasound and multi-sequence magnetic resonance imaging (MRI) for predicting survival, recurrence, and metastasis in patients diagnosed with triple-negative breast cancer (TNBC) undergoing neoadjuvant chemotherapy (NAC).
Methods: This retrospective, multicenter study included 103 patients with histopathologically confirmed TNBC across four institutions. The training group comprised 72 cases from the First People's Hospital of Lianyungang, while the validation group included 31 cases from three external centers.
Biomacromolecules
September 2025
State Key Laboratory of Molecular Engineering of Polymers, Department of Macromolecular Science, Fudan University, Shanghai 200433, China.
Triple-negative breast cancer (TNBC) remains a formidable clinical challenge due to its aggressive behavior, lack of therapeutic targets, and poor prognosis. The PI3K/AKT/mTOR pathway is highly activated in TNBC, making it a promising therapeutic target. Conventional PEGylated nanocarriers often face challenges, such as accelerated blood clearance and lysosomal trapping.
View Article and Find Full Text PDF